Core Viewpoint - The approval of JMT206 by the FDA for clinical trials in the U.S. marks a significant milestone for the company, indicating strong potential in the obesity treatment market [1] Group 1: Product Development - The company has developed a recombinant fully human anti-ActRIIA/IIB monoclonal antibody, JMT206, which has received FDA approval for clinical trials in the U.S. [1] - JMT206 has also been approved by the National Medical Products Administration (NMPA) in China for clinical trials starting in November 2025 [1] - The clinical indication for JMT206 is weight management in obese or overweight individuals with at least one weight-related comorbidity [1] Group 2: Clinical Research Findings - Preclinical studies have demonstrated high bioavailability, good efficacy, and safety for JMT206, suggesting significant clinical development value [1]

Core Viewpoint - The innovation drug sector in China is experiencing significant growth due to favorable policy developments, with the introduction of new drug listings in the national medical insurance catalog and commercial insurance, providing a stable policy outlook for innovative drug companies [1][2]. Group 1: Industry Trends - The China Hong Kong Stock Connect Innovation Drug Index increased by 0.30% as of December 11, 2025, with notable gains from companies such as Zhaoyan New Drug (+4.15%) and Rongchang Bio (+2.85%) [1]. - The national medical insurance catalog for 2025 successfully added 114 new drugs, including 50 innovative drugs, achieving a historical high success rate of 88% [1]. - The introduction of dual catalogs for medical insurance and commercial insurance is expected to directly benefit innovative drug companies, indicating a positive industry outlook [1]. Group 2: Market Opportunities - The top ten weighted stocks in the China Hong Kong Stock Connect Innovation Drug Index account for 72.68% of the index, highlighting the concentration of investment in leading innovative drug companies [2]. - The Harvest Innovation Drug ETF (520970) closely tracks the index, providing investors with access to leading companies involved in drug research, development, and production [2]. - Investors without stock accounts can leverage the Hong Kong Stock Connect Innovation Drug ETF linked fund (024700) to capitalize on the growth opportunities in the innovative drug sector [2].

Core Viewpoint - The company, Shiyao Group, has received FDA approval for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody (JMT206) to conduct clinical trials in the United States, with additional approval from China's National Medical Products Administration for trials starting in November 2025 [1] Group 1: Product Details - JMT206 specifically binds to both ActRIIA and ActRIIB receptors, blocking the interaction of activin A, myostatin, and growth differentiation factor 11 with ActRII, thereby inhibiting downstream signaling pathways [1] - The product aims to reduce muscle loss and promote skeletal muscle maintenance and growth, achieving a dual effect of muscle gain and fat loss [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in individuals who are obese or overweight and have at least one weight-related comorbidity [1] - The product is also designed to assist GLP-1 receptor agonists in achieving higher quality weight loss outcomes [1]

Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody (JMT206) to conduct clinical trials in the United States, and it has also been approved by the National Medical Products Administration of China for clinical trials in China by November 2025 [1] Group 1: Product Details - JMT206 specifically binds to Activin receptor type IIA (ActRIIA) and IIB (ActRIIB), blocking the binding of Activin A, Myostatin (GDF8), and Growth Differentiation Factor 11 (GDF11) to Activin receptor type II (ActRII) [1] - The product aims to inhibit downstream signaling pathways, reduce muscle loss, and promote skeletal muscle maintenance and growth, achieving muscle gain and fat loss [1] - It also assists GLP-1 receptor agonists in achieving higher quality weight loss effects [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in obese or overweight individuals with at least one weight-related comorbidity [1] - Preclinical studies have shown that the product exhibits high bioavailability, good efficacy, and safety, indicating a high clinical development value [1]

Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its monoclonal antibody JMT206, allowing it to conduct clinical trials in the U.S. This product has also been approved by the National Medical Products Administration of China for clinical trials starting in November 2025 [1]. Group 1 - The product JMT206 specifically binds to Activin Receptor IIA and IIB, blocking the interaction of Activin A, GDF8, and GDF11 with Activin Receptor IIB, thereby inhibiting downstream signaling pathways that lead to muscle loss [1]. - JMT206 aims to reduce muscle loss and promote skeletal muscle maintenance and growth, achieving a dual effect of muscle gain and fat loss [1]. - The clinical indication for JMT206 is weight management in obese or overweight individuals with at least one weight-related comorbidity [1]. Group 2 - Preclinical studies have demonstrated that JMT206 exhibits high bioavailability, along with good efficacy and safety, indicating significant clinical development value [1].

该产品可同时特异性结合激活素受体IIA型(ActRIIA)与IIB型(ActRIIB)，阻断激活素A(ActivinA)、肌抑 素(GDF8)以及生长分化因子11(GDF11)与激活素受体II型(ActRII)的结合，从而抑制下游信号通路的激 活，减少肌肉流失，并促进骨胳肌维持与增长，以达到增肌减脂的效果。同时，该产品亦可协助GLP-1 受体激动剂实现更高质量的减重效果。本次获批的临床适应症为肥胖或超重合并至少一种体重相关合并 症人群的体重管理。 临床前研究显示，该产品表现出较高的生物利用度以及良好的有效性和安全性，具有较高的临床开发价 值。 格隆汇12月10日丨石药集团(01093.HK)宣布，集团开发的重组全人源抗ActRIIA/IIB单克隆抗体 (JMT206)已获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。该产品亦已于2025年11月 获得中华人民共和国国家药品监督管理局批准在中国开展临床试验。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 主席 蔡東晨 重組全人源抗ACTRIIA / IIB單克隆抗體(JMT206) 在美國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的重組全人源抗Act RIIA / IIB單克隆抗體(JMT206)（「該產品」）已獲美國食品 藥品監督管理局(FDA)批准，可在美國開展臨床試驗。該產品亦已於2025年11月獲得中華人 民共和國國家藥品監督管理局批准在中國開展臨床試驗。 該 產 品 可 同 時 特 異 性 結 合 激 活 素 受 體 I IA 型 (A ct R I IA ) 與 I IB 型 (A ct R I IB ) ， 阻 斷 激 活 素 A (Activin A) 、 肌 抑 素 (GDF 8) ...

公告称，本次申请基于一项Ⅲ期临床试验。该临床试验结果表明，在非糖尿病的肥胖成人受试者中，该 产品可显著降低体重及腰围，改善血糖、血脂及肝酶水平；与诺和诺德开发的司美格鲁肽相比，其有效 性高度一致，安全性特徵相似，且耐受性良好，不良事件发生率略低。基于在疗效、安全性、制剂方面 的优势，该产品具有显著的临床应用价值。 智通财经APP获悉，石药集团(01093)尾盘涨超3%，截至发稿，涨2.92%，报7.75港元，成交额5.15亿港 元。 消息面上，12月8日，石药集团发布公告，公司附属公司石药集团百克(山东)生物制药股份有限公司开 发的司美格鲁肽注射液的第二项上市许可申请已获中华人民共和国国家药品监督管理局受理。本次申报 的适应症为在控制饮食和增加体力活动的基础上对成人超重╱肥胖患者的长期体重管理。此前，该产品 拟用于成人2型糖尿病血糖控制的适应症上市许可申请已于2025年8月获国家药监局受理。 ...

国元国际发布研报称，给予石药集团（01093）"买入"评级，目标价10.11港元，公司积极布局创新药， 研发投入加大，出海成果突出，公司持续高强度投入研发，已构建国际化管线与领先平台，出海成果显 著。尽管短期内成药业务受集采影响承压，但单季度业绩已呈现企稳回升态势，且多款核心创新药临近 关键节点，授权收入成为新增长点，为中长期增长奠定坚实基础。 国元国际主要观点如下： 新药研发投入加大，研发平台优势明显 公司已建成一支逾2000人的国际化研发团队，聚焦于抗肿瘤、精神神经、心血管等治疗领域，拥有8大 研发平台。研发费用41.85亿元，同比增长7.9%，占成药收入27.1%，显示公司持续高强度投入创新，有 近90个产品在临床试验的不同阶段，14款产品已递交上市申请，30余款处于注册临床阶段，为未来收入 结构转型奠定基础，公司计划在未来5年内申报近50款新产品/新适应症上市。 新药研发快速推进，出海成果突出 创新管线加速兑现，授权费收入15.40亿元贡献新增长极，海外授权协议累计潜在里程碑付款超150亿美 元，国际化战略成效初显。SYS6091（HER2ADC）、SYS6010（EGFRADC）、安尼妥单抗（HER ...

Group 1 - The core viewpoint of the report is that Guoyuan International has given a "Buy" rating to CSPC Pharmaceutical Group (01093) with a target price of HKD 10.11, highlighting the company's active layout in innovative drug development and significant international achievements [1] - The company has built an international R&D team of over 2,000 people, focusing on oncology, psychiatry, and cardiovascular treatments, with R&D expenses of CNY 4.185 billion, a year-on-year increase of 7.9%, representing 27.1% of the revenue from traditional drugs [1][2] - The company has nearly 90 products in various stages of clinical trials, with 14 products submitted for market approval and over 30 in the registration clinical stage, laying a solid foundation for future revenue structure transformation [1] Group 2 - The innovative pipeline is accelerating, with licensing fee income of CNY 1.54 billion contributing to new growth, and cumulative potential milestone payments from overseas licensing agreements exceeding USD 15 billion [2] - Eight products, including SYS6091 (HER2ADC) and SYS6010 (EGFRADC), are in critical clinical stages, with expected data readouts and market applications between 2025 and 2027 [2] - SYS6010 (EGFRADC) has received three fast-track designations from the FDA and breakthrough therapy recognition from NMPA, with a potential market application expected in 2026 [2] Group 3 - For the first three quarters of 2025, the company's revenue was CNY 19.891 billion, a year-on-year decline of 12.3%, with a net profit of CNY 3.511 billion, down 7.06% [3] - The decline in revenue is primarily due to the impact of centralized procurement and price reductions in the medical insurance sector, with revenue from traditional drugs dropping to CNY 15.450 billion, a decrease of 17.2% [3] - In Q3, the company's revenue was CNY 6.62 billion, a year-on-year increase of 3.4% and a quarter-on-quarter increase of 5.7%, with a net profit of CNY 0.96 billion, up 27.2% [3]